EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Aprilbio Co. Ltd. (397030) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Aprilbio Co. Ltd. KRW 4,011, price KRW 17,020, upside -76.4%, quality 29 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR

AC Thin data Oct 3, 2026

Aprilbio Co. Ltd.

397030 · KQ

Weakest SetupStrongly overvalued and low quality.

Mixed Growth (revenue 3y +121.5 %/yr in KRW)
Mixed vs. peers (3/6)
Fair value 4,011 KRW · Strongly overvalued (−76.4%)
Quality 29/100
Negative free cash flow
Narrow moat 5/100
Thin data
Watch Aprilbio Co. Ltd. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

73,300 KRW 5,400 KRW Fair Value 4,011 KRW Jul 2022 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

50‑month range 5,400 KRW – 73,300 KRW · fair‑value band 2,647 KRW – 5,014 KRW · the 17,020 KRW price screens above the 4,011 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.

Follow Aprilbio Co. in your weekly email

Every Wednesday you see whether Aprilbio Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

AprilBio Co.,Ltd. develops long-acting type biobetter and antibody biologics. The company develops antibody drugs, double antibodies, long-acting antibody drugs, long-acting protein drugs, and ADC-applied antibodies. It is developing various products for use in the treatment of rare diseases, cancer, male infertility, autoimmune and inflammatory diseases.

Show more

AprilBio Co.,Ltd. develops long-acting type biobetter and antibody biologics. The company develops antibody drugs, double antibodies, long-acting antibody drugs, long-acting protein drugs, and ADC-applied antibodies. It is developing various products for use in the treatment of rare diseases, cancer, male infertility, autoimmune and inflammatory diseases. The company was founded in 2013 and is headquartered in Chuncheon-si, South Korea.

Stock analysis

Aprilbio Co. Ltd. (397030) currently trades at 17,020 KRW, while our model-based Fair Value estimate is 4,011 KRW, 76.4% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 2,647 KRW (bear) to 5,014 KRW (bull), the price of 17,020 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Aprilbio Co. Ltd. reported revenue of 2.2B KRW in FY2025 versus 23.4B KRW in FY2021, a compound −44.8%/yr. Reported net income was −9.7B KRW in FY2025.

Key figures

Market cap 449B KRW (≈ $335M) · Return on equity −9.7% · Return on assets (EBIT) −3.3% · Operating margin −1,324% · Revenue (TTM) 725M KRW · Revenue growth (YoY) −66.6% · EPS growth (YoY) −66.9% · Free cash flow −3.6B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (medium confidence).

What moves the price

The share trades about 77% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −76%, 397030 screens richer than that median.

Fair Value models

Bear 2,647 KRW Fair Value 4,011 KRW Bull 5,014 KRW
Price 17,020 KRW · Upside -76.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 2,057 KRW 2,756 KRW 4,114 KRW 51
All 1 models by family
Asset-Based
NCAV (Graham) 2,057 KRW 2,756 KRW 4,114 KRW 51

Open the full fair value analysis →

Notify me when 397030 reaches fair value

Put 397030 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 29/100

Of which business quality 29 · Market factors (momentum, volatility) 2

Profitability 1
Margins and returns on capital today
Quality Growth 10
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 81
Balance sheet, leverage, solvency risk
Investment 41
Disciplined investing over empire-building
Low Volatility 7
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 48
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 28/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−92.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+121.5%
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+56.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
19.0% (2021) → −334.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

397030 screens overvalued: fair value 76% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Aprilbio Co. Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 607 stocks

Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −76.4% · Bottom 25%
Profitability
Return on assets −6.1% · Above median
Growth and dividend
Revenue growth −66.6% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/S (TTM) 0.46× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $504.73 $555.20 +10%
Regeneron Pharmaceuticals, Inc REGN $735.20 $1,275 +73%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Aprilbio Co. Ltd. · Fair Value
4,011 KRW −76%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Aprilbio Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/397030

Frequently asked questions

Is Aprilbio Co. Ltd. (397030) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 4,011 KRW versus a price of 17,020 KRW, about −76% upside (overvalued).
What is the fair value of 397030?
Our model-based fair value for Aprilbio Co. Ltd. is 4,011 KRW (as of Oct 3, 2026), built from audited fundamentals. The current price: 17,020 KRW.
What is the quality score of 397030?
Aprilbio Co. Ltd. has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Aprilbio Co. Ltd. (397030)?
Our model-based price target is the fair value of 4,011 KRW (as of Oct 3, 2026) from 1 valuation models. Cautious scenario 2,647 KRW, optimistic scenario 5,014 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Aprilbio Co. Ltd. stock forecast for 2026?
Our models put fair value at 4,011 KRW, about −76% upside versus a price of 17,020 KRW (overvalued). Cautious scenario 2,647 KRW, optimistic scenario 5,014 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Aprilbio Co. Ltd. (397030)?
Aprilbio Co. Ltd. reported trailing-twelve-month revenue of about 725M KRW (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Aprilbio Co. Ltd. (397030)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Aprilbio Co. Ltd. it is 4,011 KRW per share (as of Oct 3, 2026), against a price of 17,020 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Aprilbio Co. Ltd. stock overvalued or undervalued in 2026?
As of Oct 3, 2026, 397030 trades above its calculated fair value: price 17,020 KRW, fair value 4,011 KRW, a gap of about −76% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 397030?
No. The price is what the market pays today (17,020 KRW); the fair value is what the company's own numbers justify (4,011 KRW). For Aprilbio Co. Ltd. the two are 13,009 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Aprilbio Co. Ltd. worth?
The market values Aprilbio Co. Ltd. at about 449B KRW (market capitalisation, as of Oct 3, 2026). Per share that is 17,020 KRW; our models calculate a fair value of 4,011 KRW per share.
What do the bullish and bearish scenarios say about 397030?
Our models span a range for Aprilbio Co. Ltd.: cautious scenario 2,647 KRW, base 4,011 KRW, optimistic 5,014 KRW per share (as of Oct 3, 2026, price 17,020 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Aprilbio Co. Ltd. (397030)?
Balance-sheet figures for Aprilbio Co. Ltd. (as of Oct 3, 2026): return on equity −9.7%. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is 397030 from its 52-week high?
Aprilbio Co. Ltd. trades at 17,020 KRW, about 77% below its 52-week high of 73,300 KRW and 1% above the low of 16,770 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 4,011 KRW is for.
Which stocks are comparable to Aprilbio Co. Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Aprilbio Co. Ltd. stock attractive at the current price?
The data as of Oct 3, 2026: price 17,020 KRW, calculated fair value 4,011 KRW (−76%), Quality Score 29/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 397030 calculated?
We run Aprilbio Co. Ltd. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 4,011 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. Aprilbio Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Aprilbio Co. Ltd. (397030)?
The closing price on Oct 2, 2026 was 17,020 KRW. Our model-based fair value is 4,011 KRW, about −76% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Aprilbio Co. Ltd. right now?
The price sits above even our optimistic bull case (5,014 KRW). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (2,647 KRW to 5,014 KRW) leaves room in how you read the outcome.

Key figures of Aprilbio Co. Ltd.

How large is the market capitalisation of Aprilbio Co. Ltd. (397030)?
The market capitalisation of Aprilbio Co. Ltd. is 449B KRW (≈ $335M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the return on equity of Aprilbio Co. Ltd. (397030)?
The return on equity (ROE) of Aprilbio Co. Ltd. is −9.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Aprilbio Co. Ltd. (397030)?
On an EBIT basis the return on assets of Aprilbio Co. Ltd. is −3.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Aprilbio Co. Ltd. (397030)?
The operating margin of Aprilbio Co. Ltd. is −1,324% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Aprilbio Co. Ltd. (397030)?
Revenue at Aprilbio Co. Ltd. is growing −66.6% versus a year earlier (3y avg +121%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Aprilbio Co. Ltd. (397030)?
Earnings per share at Aprilbio Co. Ltd. are growing −66.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Aprilbio Co. Ltd. (397030) generate?
The free cash flow of Aprilbio Co. Ltd. is −3.6B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Aprilbio Co. Ltd. in the live analysis

One click puts Aprilbio Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.